Respiratory Distress Syndrome, Adult Clinical Trial
Official title:
Adaptive Support Ventilation vs. Conventional Ventilation Strategy in the Management of Acute Respiratory Distress Syndrome:A Randomized Controlled Trial
Prospective randomized controlled trial to be conducted in the Respiratory Intensive Care
Unit (RICU) of Post Graduate Institute of Medical Education And Research
(PGIMER),Chandigarh. The study is approved by the Institute Ethics committee. In view of
lack of previous outcome data in such patients, all patients requiring RICU admission for
acute respiratory distress syndrome(ARDS) between January 2010 and June 2011 are being
enrolled in this pilot study.
The patients meeting the aforementioned criteria will randomly assigned to ventilation with
assist control mode ventilation (ACMV group) as per the ARDSnet strategy or adaptive support
ventilation (ASV group). Being the first RCT of its type, patients will be first stabilized
on ACMV for 1 hour to determine the adequate minute ventilation. The randomization sequence
will be computer generated. The assignments will placed in sealed opaque envelopes and each
patient's assignment was made on admission to the RICU by the attending physician. Blinding
of treatment is not possible.
All patients will be ventilated only by Galileo Gold ventilators (Hamilton medical systems,
Bonaduz, Switzerland). Patients randomized to the ACMV group will be ventilated according to
low tidal volume strategy of 6ml/kg with Fio2/PEEP as per ARDSnet table to achieve a
saturation between 88-95% with the lowest possible Fio2 to maintain plateau pressures < 30
cms H2o and PH > 7.3 with option to reduce tidal volume to 4 ml/kg and increase respiratory
rate to 35/ min to achieve the above said goals11.These patients will be weaned as per
standard protocol of spontaneous breathing trial of 30 minutes once they are recognized
eligible as per statement of the sixth International consensus conference on weaning.
Inclusion criteria:
Study to include at least 40 patients admitted to RICU with diagnosis of ARDS as defined by
American European consensus committee in 1994.
1. Acute onset shortness of breath(<7 days)
2. PaO2/FiO2 < 200 mm Hg (regardless of PEEP)
3. Bilateral infiltrates on frontal chest radiograph
4. <18 mm Hg when measured or no clinical evidence of left atrial hypertension
Exclusion criteria:
1. Age less than 12 years
2. Patients having underlying chronic lung disease (COPD, interstitial lung disease,
pulmonary hypertension)
3. Contraindication to permissive hypercapnea (raised intracranial pressure, acute
cerebrovascular disorders, acute or chronic myocardial ischemia, right ventricular
failure, uncorrected severe metabolic acidosis, sickle cell anemia, tricyclic
antidepressant overdose, pregnancy)
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03712215 -
STUDY OF ELECTRICAL STIMULATION IN PULMONARY FUNCTION IN INTENSIVE CARE UNIT
|
N/A | |
| Completed |
NCT04582201 -
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01990456 -
Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study
|
N/A | |
| Completed |
NCT01167621 -
Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation
|
N/A | |
| Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
| Completed |
NCT00029328 -
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT00004494 -
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
|
Phase 1 | |
| Completed |
NCT00000579 -
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
|
Phase 3 | |
| Recruiting |
NCT03236272 -
Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)
|
||
| Withdrawn |
NCT04508933 -
Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and "Typical"ARDS Patients
|
||
| Completed |
NCT02273687 -
Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department
|
N/A | |
| Recruiting |
NCT03424798 -
Measuring Heart and Lung Function in Critical Care
|
N/A | |
| Recruiting |
NCT01992237 -
Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients
|
N/A | |
| Completed |
NCT00719446 -
Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials
|
N/A | |
| Completed |
NCT00236262 -
Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT00300248 -
Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT00157144 -
Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005
|
N/A | |
| Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT00465374 -
A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients
|
Phase 3 | |
| Completed |
NCT00094406 -
Carbon Monoxide to Prevent Lung Inflammation
|
Phase 1 |